
Finding or detecting cancer at an early stage can make it much more treatable. Molecular staging of cancer has the potential of being able to recognize subsets of the disease to allow for highly targeted therapies that can yield unprecedented results. Commercial tests need to be able to diagnose cancer with an exquisite sensitivity with just a few cells, to overcome the challenge of the heterogeneity of cancer. Plan to attend to learn what progress has been made towards developing assays with specific biomarkers to cancer that will create a new generation of products.
Technologies Include:
Addressing challenges with circulating tumor cells
Advances in deep sequencing of cancer
Blood-based, non-invasive early detection
Detection of cancer related low abundance proteins
Cancer-type specific vs. pan-cancer approaches
Strategies for improved prognostic markers
Overcoming barriers to clinical adoption
Crossing reimbursement and regulatory hurdles
If you would like to submit a proposal to give a podium presentation or display a poster at this meeting, please click here to submit a title and brief 3-5 sentence summary of a proposed topic on your recent work in the area of cancer diagnostics.
The deadline for submission is February 12, 2010.
All proposals are subject to review by the Scientific Advisory Committee to ensure the overall quality of the conference program.
For more information, please contact
Christina Lingham
Cambridge Healthtech Institute
250 First Ave, Suite 300
Needham, MA 02494
Tel: 781-972-5464
Fax: 781-972-5425
email: clingham@healthtech.com
For information on sponsorships and exhibits, please contact:
Arnie Wolfson
Manager, Business Development
Tel: 781-972-5431
email: awolfson@healthtech.com